4 papers in the library · publishing 2022-2026
May 27, 2026 James Phelps
A new randomized trial found serial intravenous ketamine was not significantly more effective than the active placebo midazolam in reducing depressive symptoms or improving quality of life. While the study may have been underpowered due to a small sample size (n=63), the improvement in MADRS scores fell short of the minimal clinically important difference. The study faced blinding failures,...
May 27, 2026 James Phelps
Een nieuwe gerandomiseerde studie toonde aan dat seriële intraveneuze ketamine niet significant effectiever was dan het actieve placebo midazolam bij het verminderen van depressieve symptomen of het verbeteren van de kwaliteit van leven. Hoewel de studie mogelijk onvoldoende power had door een kleine steekproefomvang (n=63), bleef de verbetering in MADRS-scores ruim onder het minimaal klinisch...
January 25, 2023 James Phelps
For the treatment of major depression, electroconvulsive therapy (ECT) is markedly more effective than ketamine, per this meta-analysis of 6 randomized head-to-head comparison studies, at the end of 3–4 weeks of treatment. In 2 of these studies that measured longer-term outcomes (i.e., 2 and 10 months after treatment, respectively), no difference was found in ketamine vs ECT.
December 27, 2022 James Phelps
A randomized trial of MDMA as an adjunct to psychotherapy for PTSD found it superior to placebo plus the same manualized therapy (effect size 0.9). However, the blinding in that study almost completely failed. Vocal public advocacy for psychedelics as adjuncts to psychotherapy is creating an environment of high positivity bias that is affecting research quality and results. Thus, a recent...